Orient Biotech(SH:688298)2021-04-28 16:00Financial Performance - Net profit attributable to shareholders reached CNY 1,186,355,315.52, a significant increase of 2,601.42% year-on-year[14]. - Operating revenue surged to CNY 2,235,856,344.48, reflecting a year-on-year growth of 1,925.91%[14]. - Basic earnings per share reached CNY 9.89, up 2,572.97% from CNY 0.37 in the previous year[14]. - The net profit after deducting non-recurring gains and losses was CNY 1,184,005,687.52, an increase of 2,660.48% year-on-year[14]. - The total net profit for the quarter included non-recurring gains of CNY 2,349,628.00[17]. - Operating profit for Q1 2021 was ¥1,377,376,219.57, up from ¥53,542,455.32 in Q1 2020, reflecting a growth of 2,570.5%[53]. - Net profit attributable to shareholders for Q1 2021 was ¥1,186,355,315.52, compared to ¥43,916,037.42 in Q1 2020, marking an increase of 2,694.5%[55]. - The company achieved a total comprehensive income of ¥1,188,111,525.52 in Q1 2021, significantly higher than ¥45,990,149.80 in Q1 2020, an increase of 2,480.5%[55]. Asset and Equity Growth - Total assets increased by 38.80% to CNY 4,959,720,348.96 compared to the end of the previous year[14]. - The company reported a significant increase in net assets attributable to shareholders, which rose by 48.58% to CNY 3,634,420,579.62 compared to the end of the previous year[14]. - The total equity attributable to the parent company increased to ¥3,634,420,579.62, a rise of 48.58% compared to ¥2,446,042,711.91 in the same period last year, driven by significant operational performance growth[28]. - The company's equity attributable to shareholders rose to approximately ¥3.63 billion, compared to ¥2.45 billion, indicating a growth of 48.3% year-over-year[48]. Cash Flow and Liquidity - Net cash flow from operating activities increased by 792.53% to CNY 1,277,675,312.02 compared to the same period last year[14]. - Cash received from sales of goods and services was ¥2,183,953,382.26, a 736.60% increase from ¥261,052,173.49[28]. - The net increase in cash and cash equivalents was CNY 992.42 million, compared to CNY 86.61 million in the same quarter last year[67]. - The ending balance of cash and cash equivalents was CNY 2.79 billion, up from CNY 171.96 million in the previous year[67]. Research and Development - Research and development expenses accounted for 1.04% of operating revenue, a decrease of 6.09 percentage points year-on-year[14]. - Research and development expenses increased to ¥23,299,512.68, a 195.99% rise from ¥7,871,766.61, reflecting enhanced investment in new product development[28]. - Research and development expenses in Q1 2021 totaled ¥23,299,512.68, which is an increase of 195.5% from ¥7,871,766.61 in Q1 2020[53]. Inventory and Liabilities - Inventory rose by 62.47% to ¥619,944,913.78 from ¥381,578,076.46, reflecting a substantial increase in orders[25]. - Current liabilities totaled approximately ¥1.31 billion, compared to ¥1.11 billion, reflecting an increase of 17.8% year-over-year[46]. - Total liabilities increased to approximately ¥1.32 billion, up from ¥1.12 billion, representing a growth of 18.7% year-over-year[48]. - Accounts payable rose to approximately ¥623.57 million, up from ¥371.97 million, marking a significant increase of 77.5% year-over-year[42]. Tax and Other Financial Metrics - Tax payable increased by 48.75% to ¥521,359,318.36 from ¥350,489,621.78, mainly due to an increase in income tax payable[25]. - The company reported a tax expense of ¥191,285,405.64 for Q1 2021, compared to ¥7,736,910.32 in Q1 2020, indicating a rise of 2,373.5%[53]. - Other comprehensive income after tax for Q1 2021 was ¥2,022,552.19, compared to ¥327,527.75 in Q1 2020, reflecting a growth of 517.5%[55]. Shareholder Information - The company has a total of 12,837 shareholders, with the top ten shareholders holding significant stakes[21].